Ağız kuruluğunun etiyolojisi ve tedavisinde günümüzdeki yaklaşım

Year 2005, Volume: 12 Issue: 4, 58 - 67, 16.04.2009

A.diljin Keçeci , Feyza Özdemir

Abstract

SüleymanDemirel Üniversitesi
TIP FAKÜLTESİ DERGİSİ: 2005 Aralık; 12(4)








Ağız kuruluğunun etiyolojisi ve tedavisinde günümüzdeki yaklaşım



A. Diljin Keçeci, Feyza Özdemir



Özet

Ağız kuruluğu, hastaya ait subjektif rahatsızlık yaratmasının yanı sıra tükrüğün fizyolojik yıkama etkisinin ortadan kalkması ve ağız florasında ortaya çıkan değişikliklerle diş çürüklerinde anlamlı düzeyde artışa neden olur. Bu nedenle ağız kuruluğuna neden olan hastalıklar ve ilaç kullanımının veya radyoterapinin etkilerinin bilinmesi bu terapiyi yapan hekim ve dişhekiminin önemli bir sorumluluğudur. Bunun yanında hastaların oral hijyen şartlarının iyleştirilmesi ve ağız kuruluğunu önleyici tedaviler konusunda bilgilendirilmeleri gerekir.



Anahtar kelimeler: ağız kuruluğu, etiyoloji, kemoterapi, radyoterapi, pilokarpin, tükrük destekleyiciler



Abstract



Contemporary approach to the etiology and therapy of xerostomia

It is well known that xerostomia causes subjective discomfort of the patient and also alterations of oral microflora due to loss of washing effect of saliva resulting in a significant caries incidence. Therefore, the knowledge on the effects of diseases, medications or radiotherapy which cause xerostomia is an important responsibility of both, for a physician or dentist. Besides, patients should be informed about the change of oral hygen conditions and preventive measures against xerostomia.



Key words: Xerostomia,etyology, chemotherapy, radiotherapy, pilokarpin salivary substitutes

Keywords

aðýz kuruluðu, etiyoloji, kemoterapi, radyoterapi, pilokarpin, tükrük destekleyiciler

References

• Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety,depression and stress. J Dent Res 2000;79:1652-8.
• Berne RM. Physiology. 4th ed. St Louis (MO): Mosby, 1998;619-21.
• Carlson GW. The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am 2000;80:261-73.
• Nagler RM. Salivary glands and the aging process: mechanistic aspects, health-status and medicinal- efficacy monitoring.Biogerontology. 2004;5:223-33.
• Porter SR, Scully C. Adverse drug reactions in the mouth. Clin Dermatol 2000;18:525-32.
• Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
• Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998;159:1245-52.
• Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995;40:983-9.
• Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 1997;58:112-8.
• Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ, Thompson RP. Omeprazole and dry mouth. Scand J Gastroenterol 1995;30:216-8.
• Bruera E, Belzile M, Neumann CM, Ford I, Harsanyi Z, Darke A. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain.A randomized controlled trial. Support Care Cancer 1999;7: 280-3.
• Hill JL, Zacny JP. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology (Berl) 2000; 152:31-9.
• Chilla R, Arglebe C. Pharmacotherapy of hypertension and its significance for the function of the salivary glands (author’s translation). MMW Munch Med Wochenschr 1975;117:1425-8.
• Schoenberger JA, Croog SH, Sudilovsky A, Levine S, Baume RM. Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group. Am J Hypertens 1990;3:123-32.
• Croog SH, Elias MF, Colton T, Baume RM, Leiblum SR, Jenkins CD, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994;7:329-39.
• Nederfors T. Xerostomia: prevalence and pharmacotherapy. With special reference to beta- adrenoceptor antagonists. Swed Dent J Suppl 1996;116:1-70.
• Öktem F, Uzel Ö, Ada M, Toprak M, Cansýz H, .Gülen H, Tuksan K Nazofarinks Kanserli Hastalarda Radyoterapi Sonras›Kulak Burun Boðaz Morbiditesi. Türk Otolarengoloji Arþivi, 2001;39:121-26
• Epstein JB, Stevenson-Moore P, Scully C. Management of xerostomia. J Can Dent Assoc 192;58:140-3.
• Epstein JB, van der Meji EH, Lunn R, Steverson- Moore P. Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:268- 75
• Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 J;97:28- 46.
• Singh N, Scully C, Joyston-Bechal S. Oral complications of cancer therapies: prevention and management. Clin Oncol (R Coll Radiol) 1996;8:15- 24.
• Pow EH, McMillan AS, Leung WK, Wong MC, Kwong DL. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma. Clin Oral Investig 2003;7(4):230-4.
• Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage 2001;22:820-50.
• Yücel E, Delibaþý E, Pediatrik kanser hastalarýnda kemoterapinin neden olduðu oral komplikasyonlar (Bir vaka nedeniyle) GÜ Diþhek Fak Derg 1986;3:161-8..
• Ackerstaff AH, Tan IB, Rasch CR, Balm AJ, Keus RB, Schornagel JH, et al. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2002;128:1185-90.
• Nagler RM. Effects of radiotherapy and chemotherapeutic cytokines on a human salivary cell line. Anticancer Res 1998;18: 309-14.
• Nagler RM, Sherman Y, Nagler A. Histopathological study of the human submandibular gland in graft versus host disease. J Clin Pathol 1999;52:395-7.
• Levy S, Nagler A, Okon S, Marmary Y. Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model. Bone Marrow Transplant 2000;25:1073-8.
• Demarosi F, Bez C, Sardella A, Lodi G, Carrassi A. Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation. Arch Dermatol 2002;138: 842-3.
• Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson DE, Flournoy N, et al. Oral manifestations of chronic graft-vhost disease. Arch Intern Med 1984;144:1591-5.
• Janin-Mercier A, Saurat JH, Bourges M, Sohier J, Jean LD, Gluckman E. The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases. Acta Derm Venereol 1981;61:187-93.
• Nicolatou-Galitis O, Kitra V, Van Vliet-Constantinidou C, Peristeri J, Goussetis E, Petropoulos D, et al. The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med 2001;30:148- 53.
• Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000;12:391-8.
• Bowman SJ. Collaborative research into outcome measures in Sjögren’s syndrome. Update on disease assessment. Scand J Rheumatol Suppl 2002;116:23- 7.
• Ohtsuka S, Yanadori A, Tabata H, Yamakage A, Yamazaki S. Sarcoidosis with giant parotomegaly. Cutis 2001;68:199-200.
• Drosos AA, Voulgari PV, Psychos DN, Tsifetaki N, Bai M. Sicca syndrome in patients with sarcoidosis. Rheumatol Int 1999;18:177-80.
• Mbopi-Keou FX, Belec L, Teo CG, Scully C, Porter SR. Synergism between HIV and other viruses in the mouth. Lancet Infect Dis 2002;2:416-24
• Franco-Paredas C, Rebolledo P, Folch E, Hernandez I, del Rio C. Diagnosis of diffuse CD8+ lymphocytosis syndrome in HIV-infected patients. AIDS Read 2002;12:408-13
• Pedersen AM, Nauntofte B. Primary Sjögren’s syndrome: oral aspects on pathogenesis, diagnostic criteria, clinical features and approaches for therapy. Expert Opin Pharmacother 2001; 2:1415-36.
• Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Arch Med Res 2002;33:95- 106.
• Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000;29:20-8.
• Hay KD, Morton RP, Wall CR. Quality of life and nutritional studies in Sjögren’s syndrome patients with xerostomia. N Z Dent J 2001;97:128-31.
• Rostron J, Rogers S, Longman L, Kaney S, Field EA. Health related quality of life in patients with primary Sjogren’s syndrome and xerostomia: a comparative study. Gerodontology 2002;19:53-9.
• Little JW, Falace DA, Miller CS, Rhodus NL. Dental manegement of medically compromised patient (5th Ed) St Louis, Mosby, 1997;630-31.
• Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren’s syndrome. Scand J Rheumatol 2000;29:341-8.
• al-Hashimi I, Taylor SE. A new medication for treatment of dry mouth in Sjögren’s syndrome. Tex Dent J 2001;118:262-6.
• Meyer-Lueckel H, Kielbassa AM. Use of saliva substitutes in patients with xerostomia. Schweiz Monatsschr Zahnmed 2002; 112:1037-58.
• Senahayake F, Piggott K, Hamilton-Miller JM. A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. Curr Med Res Opin 1998;14:155-9.
• Warde P, Kroll B, O’Sullivan B, Aslanidis J, Tew- George E, Waldron J, et al. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 2000;8:203-8.
• Epstein JB, Emerton S, Le ND, Stevenson-Moore P. A double blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 1999;35:132-7.
• Epstein JB, Stevenson-Moore P. A clinical comparative trial of saliva substitutes and radiation-induced salivary gland hypofunction. Spec Care Dentist 1992;12:21-3.
• Samarawickrama DY. Saliva substitutes: how effective and safe are they? Oral Dis 2002;8:177-9.
• Hooper P, Tincello DG, Richmond DH. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. Br J Urol 1997;80:414-6.
• Momm F, Guttenberger R. Treatment of xerostomia following radiotherapy: does age matter? Support Care Cancer 2002;10: 505-8
• Rhodus NL, Bereuter J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren’s syndrome. J Otolaryngol 2000;29:28- 34.
• Criswell MA, Sinha CK. Hyperthermic, supersaturated humidification in the treatment of xerostomia. Laryngoscope 2001; 111:992-6.
• Frost PM, Shirlaw PJ, Walter JD, Challacombe SJ. Patient preferences in a preliminary study comparing an intra-oral lubricating device with the usual dry mouth lubricating methods. Br Dent J 2002;193:403- 8.
• Fox RI, Michelson P. Approaches to the treatment of Sjogren’s syndrome. J Rheumatol Suppl 2000;61:15- 21.
• Vivino FB. The treatment of Sjögren’s syndrome patients with pilocarpine-tablets. Scan J Rheumatol Suppl 2001;115:1-9.
• Aromdee C, Ferguson MM, Ledger R, Wall J. A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose. Eur J Pharm Sci 1999;8:81-3.
• Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren’s syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159: 174-81.
• Bell M, Askari A, Bookman A, Frydrych S, Lamont J, McComb J, et al. Sjögren’s syndrome: a critical review of clinical management. J Rheumatol 1999;26:2051-61.
• Taylor SE, Miller EG. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Proc Soc Exp Biol Med 1999;221:14-26.
• Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18: 3339-45.
• Buntzel J, Glatzel M, Kuttner K, Weinaug R, Frohlich D. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002;12:4-13.
• Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs
• Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
• Valdez IH, Wolff A, Atkinson JC, Macynski AA, Fox PC. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71:1848-51.
• Joensuu H, Bostrom P, Makkonen T. Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. Radiother Oncol 1993;26:33-7.
• Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996;106:972-6.
• Jacobs CD, van der Pas M. A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Huntingt) 1996;10:16-20.
• Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987;59:1123-5.
• Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991; 151:1149-52.
• Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 2003:14:213-25.
• LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A mulitcenter, randomized, doubleblind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-31.
• Ferguson MM. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1993;75:186-91.
• Cooper RA, Cowan RA, Owens SE, Jeans SP, Roberts JK, Hillel PG, et al. Does salivary gland scintigraphy predict response to pilocarpine in patients with post- radiotherapy xerostomia? Eur J Nucl Med 1999;26:220- 5.
• Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000;55:233-9.
• Niedermeier W, Matthaeus C, Meyer C, Staar S, Muller RP, Schulze HJ. Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:541-9.
• Lajtman Z, Krajina Z, Krpan D, Vincelj J, Borcic V, Popovic- Kovacic J. Pilocarpine in the prevention of postirradiation xerostomia. Acta Med Croatica 2000;54:65-7.
• Frydrych AM, Davies GR, Slack-Smith LM, Heywood J. An investigation into the use of pilocarpine as a sialogogue in patients with radiation induced xerostomia. Aust Dent J 2002; 47:249-53.
• Anonymous. Oral pilocarpine: new preparation. Xerostomia after radiation therapy: moderately effective but costly. Prescrire Int 2002;11:99-101.
• Warde P, O’Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for headand- neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9-13.
• Itthagarun A, Wei SH. Chewing gum and saliva in oral health. J Clin Dent 1997;8:159-62.
• Warde P, Kroll B, O’Sullivan B, Aslanidis J, Tew- George E, Waldron J, et al. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 2000;8:203-8.
• Davies AN. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med 2000;14:197- 203.
• Erlichman M. Patient selection criteria for electrostimulation of salivary production in the treatment of xerostomia secondary to Sjogren’s syndrome. Health Technol Assess Rep 1990;8:1-7.
• Blom M, Dawidson I, Angmar-Mansson B. The effect of acupuncture on salivary flow rates in patients with xerostomia. Oral Surg Oral Med Oral Pathol 1992;73:293-8.
• Blom M, Dawidson I, Fernberg JO, Johnson G, Angmar-Mansson B. Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 1996;32B:182- 90.
• Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000;6:15- 24.
• Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys
• List T, Lundeberg T, Lundstrom I, Lindstrom F, Ravald N. The effect of acupuncture in the treatment of patients with primary Sjögren’s syndrome. A controlled study. Acta Odontol Scand 1998;56:95-9.
• Rydholm M, Strang P. Acupuncture for patients in hospitalbased home care suffering from xerostomia. J Palliat Care 1999;15:20-3.
• Johnstone PA, Niemtzow RC, Riffenburgh RH. Acupuncture for xerostomia: clinical update. Cancer
• Pedersen A, Gerner N, Palmvang I, Hoier-Madsen M. Longo- Vital in the treatment of Sjögren’s syndrome. Clin Exp Rheumatol 1999;17:533-8.
• Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjögren’s syndrome, systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol Suppl 1986;61:242-5.
• Oxholm P, Manthorpe R, Prause JU, Horrobin D. Patients with primary Sjogren’s syndrome treated for two months with evening primrose oil. Scand J Rheumatol 1986;15:103-8.
• Belch JJ, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 2000;71:352S-6S.
• Chodorowski Z. Cappuccino coffee treatment of xerostomia in patients taking tricyclic antidepressants: preliminary report. Przegl Lek 2002;59:392-3.
• Johansson G, Andersson G, Edwardsson S, Bjorn AL, Manthorpe R, Attstrom R. Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren’s syndrome.
• A double-blind crossover investigation. Gerodontology 2001;18:87-94.